← Oncology Approval Tracker

FDA DECISION ·

Lutathera

lutetium Lu 177 dotatate · Advanced Accelerator Applications USA (Novartis)

FDA approvalNew or expanded indicationGastroenteropancreatic neuroendocrine tumors
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Patients aged 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut and hindgut tumors.

LAMPGEN ANALYSIS

Why it matters

The label expanded a targeted radioligand option to adolescents with rare neuroendocrine tumors.

What research teams should watch

Coordinate receptor imaging, amino acid infusion, radiation precautions and family education across nuclear medicine and pediatric oncology.

PRIMARY RECORDS

Sources